Inceptionr LLC Makes New Investment in Merit Medical Systems, Inc. $MMSI

Posted by Brian Himes on Jul 26th, 2026

Inceptionr LLC acquired a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) in the 1st quarter, Holdings Channel reports. The fund acquired 7,093 shares of the medical instruments supplier’s stock, valued at approximately $489,000.

A number of other large investors have also recently made changes to their positions in MMSI. Gibbs Wealth Management lifted its holdings in shares of Merit Medical Systems by 67.0% during the first quarter. Gibbs Wealth Management now owns 11,602 shares of the medical instruments supplier’s stock worth $800,000 after purchasing an additional 4,656 shares during the period. Sei Investments Co. increased its holdings in Merit Medical Systems by 53.2% in the 1st quarter. Sei Investments Co. now owns 228,544 shares of the medical instruments supplier’s stock worth $15,754,000 after buying an additional 79,374 shares during the period. Lido Advisors LLC raised its position in Merit Medical Systems by 13.7% during the 1st quarter. Lido Advisors LLC now owns 4,360 shares of the medical instruments supplier’s stock worth $301,000 after buying an additional 524 shares during the last quarter. CI Investments Inc. lifted its stake in Merit Medical Systems by 6.3% during the 1st quarter. CI Investments Inc. now owns 43,614 shares of the medical instruments supplier’s stock valued at $3,006,000 after acquiring an additional 2,599 shares during the period. Finally, First Trust Advisors LP lifted its stake in Merit Medical Systems by 479.1% during the 1st quarter. First Trust Advisors LP now owns 35,907 shares of the medical instruments supplier’s stock valued at $2,475,000 after acquiring an additional 29,706 shares during the period. 99.66% of the stock is owned by hedge funds and other institutional investors.

Merit Medical Systems Price Performance

NASDAQ:MMSI opened at $74.32 on Friday. The stock has a 50 day moving average of $68.19 and a two-hundred day moving average of $72.13. Merit Medical Systems, Inc. has a 12 month low of $59.74 and a 12 month high of $94.75. The firm has a market cap of $4.43 billion, a P/E ratio of 32.17, a price-to-earnings-growth ratio of 2.31 and a beta of 0.52. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.10. The firm had revenue of $381.88 million for the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. Merit Medical Systems’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, analysts expect that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current fiscal year.

Insider Activity at Merit Medical Systems

In other news, insider Brian G. Lloyd bought 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the transaction, the insider directly owned 2,000 shares in the company, valued at $125,240. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director directly owned 7,809 shares in the company, valued at approximately $488,921.49. The trade was a 39.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MMSI. Needham & Company LLC cut their price target on Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Compass Point set a $107.00 target price on Merit Medical Systems in a research note on Monday, April 20th. Wall Street Zen lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Weiss Ratings cut Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, Canaccord Genuity Group decreased their price target on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merit Medical Systems currently has an average rating of “Moderate Buy” and a consensus price target of $92.80.

View Our Latest Analysis on Merit Medical Systems

About Merit Medical Systems

(Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.